BioCentury
ARTICLE | Clinical News

Unituxin dinutuximab regulatory update

June 1, 2015 7:00 AM UTC

EMA’s CHMP recommended approval of Unituxin dinutuximab from United Therapeutics to treat high-risk neuroblastoma in patients aged 12 months to 17 years. Specifically, it is recommended in combination...